Targeting Epigenetic Modifiers: Promising Strategies for Cancer Therapy
and Beyond

Dilip   Kumar   Chanchal; Prateek      Porwal; Nidhi      Mittal

doi:10.2174/0115748855275769231114094037

Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.

Abstract

Epigenetic changes are important for controlling how genes are expressed and how cells work, and their misregulation has been linked to many diseases, including cancer. Targeting epigenetic modifiers has become a promising way to treat cancer, and it may also be useful outside of oncology. This review article goes into detail about the rapidly changing field of epigenetic-based therapies, with a focus on how they are used to treat cancer. We discuss in-depth the main epigenetic changes seen in cancer, such as DNA methylation, changes to histones, and dysregulation of noncoding RNA, as well as their roles in tumour growth, metastasis, and drug resistance. Epigenetic drugs and small molecule inhibitors that target epigenetic enzymes and reader proteins have shown a lot of promise in both preclinical and clinical studies on different types of cancer. We show the most recent evidence that these epigenetic therapies work and look into how they might be used in combination with other treatments. We talk about new research into the therapeutic potential of epigenetic modifiers in diseases other than cancer, such as neurological disorders, autoimmune diseases, and heart conditions. Even though there is a lot of potential for therapy, there are still problems, such as side effects and differences between patients. We talk about the work that is still being done to get around these problems and explain new ways to deliver epigenetic-based interventions that are more precise and effective. For epigenetic-based therapies to be used in clinical settings, it is important to understand how they work and how they interact with other types of treatment. As the field moves forward, we try to figure out where it is going and what it means to target epigenetic modifiers in cancer therapy and other areas of disease. This review looks at the role of epigenetic modulation in shaping the landscape of precision medicine and its possible effects on human health from a broad and forward-looking point of view.

[1]
Pal S, Tyler JK. Epigenetics and aging. Sci Adv  2016; 2(7): e1600584.
 [http://dx.doi.org/10.1126/sciadv.1600584] [PMID: 27482540]

[2]
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE commission for classification and terminology. Epilepsia  2017; 58(4): 512-21.
 [http://dx.doi.org/10.1111/epi.13709] [PMID: 28276062]

[3]
Ohkura N, Sakaguchi S. Transcriptional and epigenetic basis of Treg cell development and function: Its genetic anomalies or variations in autoimmune diseases. Cell Res  2020; 30(6): 465-74.
 [http://dx.doi.org/10.1038/s41422-020-0324-7] [PMID: 32367041]

[4]
Kagohara LT, Stein-O’Brien GL, Kelley D, et al. Epigenetic regulation of gene expression in cancer: Techniques, resources and analysis. Brief Funct Genomics  2018; 17(1): 49-63.
 [http://dx.doi.org/10.1093/bfgp/elx018] [PMID: 28968850]

[5]
Lyko F. The DNA methyltransferase family: A versatile toolkit for epigenetic regulation. Nat Rev Genet  2018; 19(2): 81-92.
 [http://dx.doi.org/10.1038/nrg.2017.80] [PMID: 29033456]

[6]
Stefanatos R, Sanz A. The role of mitochondrial ROS in the aging brain. FEBS Lett  2018; 592(5): 743-58.
 [http://dx.doi.org/10.1002/1873-3468.12902] [PMID: 29106705]

[7]
Gonzales MM, Garbarino VR, Pollet E, et al. Biological aging processes underlying cognitive decline and neurodegenerative disease. J Clin Invest  2022; 132(10): e158453.
 [http://dx.doi.org/10.1172/JCI158453] [PMID: 35575089]

[8]
Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr  2019; 43(2): 181-93.
 [http://dx.doi.org/10.1002/jpen.1451] [PMID: 30288759]

[9]
Nirmaladevi R, Paital B, Jayachandran P, Padma PR, Nirmaladevi R. Epigenetic alterations in cancer. Front Biosci  2020; 25(6): 1058-109.
 [http://dx.doi.org/10.2741/4847] [PMID: 32114424]

[10]
Hata A, Lieberman J. Dysregulation of microRNA biogenesis and gene silencing in cancer. Sci Signal  2015; 8(386): 3.
 [http://dx.doi.org/10.1126/scisignal.2005825]

[11]
Harper K. Plagues upon the earth: disease and the course of human history. Princeton University Press 2021.

[12]
Berdasco M, Esteller M. Clinical epigenetics: Seizing opportunities for translation. Nat Rev Genet  2019; 20(2): 109-27.
 [http://dx.doi.org/10.1038/s41576-018-0074-2] [PMID: 30479381]

[13]
Berk LE. Development through the lifespan. Sage Publications 2022.

[14]
Monk D, Mackay DJG, Eggermann T, Maher ER, Riccio A. Genomic imprinting disorders: Lessons on how genome, epigenome and environment interact. Nat Rev Genet  2019; 20(4): 235-48.
 [http://dx.doi.org/10.1038/s41576-018-0092-0] [PMID: 30647469]

[15]
Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Semin Cancer Biol  2022; 83: 452-71.
 [http://dx.doi.org/10.1016/j.semcancer.2020.07.015] [PMID: 32814115]

[16]
Li F, Qasim S, Li D, Dou QP. Updated review on green tea polyphenol epigallocatechin-3-gallate as a cancer epigenetic regulator. Semin Cancer Biol  2022; 83: 335-52.
 [http://dx.doi.org/10.1016/j.semcancer.2020.11.018] [PMID: 33453404]

[17]
Sharma R, Prajapati PK. Predictive, preventive and personalized medicine: Leads from ayurvedic concept of Prakriti (human constitution). Curr Pharmacol Rep  2020; 6(6): 441-50.
 [http://dx.doi.org/10.1007/s40495-020-00244-3]

[18]
Meloni M. Impressionable biologies: from the archaeology of plasticity to the sociology of epigenetics.  New York 2019; p. 232.
 [http://dx.doi.org/10.4324/9781315169583]

[19]
Buklijas T. Histories and meanings of epigenetics. In: The palgrave handbook of biology and society.   2018; pp. 167-87.
 [http://dx.doi.org/10.1057/978-1-137-52879-7_8]

[20]
Stricker SH, Köferle A, Beck S. From profiles to function in epigenomics. Nat Rev Genet  2017; 18(1): 51-66.
 [http://dx.doi.org/10.1038/nrg.2016.138] [PMID: 27867193]

[21]
Mercier R, Mézard C, Jenczewski E, Macaisne N, Grelon M. The molecular biology of meiosis in plants. Annu Rev Plant Biol  2015; 66(1): 297-327.
 [http://dx.doi.org/10.1146/annurev-arplant-050213-035923] [PMID: 25494464]

[22]
Ozernyuk ND. From template principle of Nikolai K. Koltzov to the double helix model of DNA structure. Russ J Dev Biol  2022; 53(1): 1-5.
 [http://dx.doi.org/10.1134/S1062360422010064]

[23]
Blunk I, Thomsen H, Reinsch N, et al. Genomic imprinting analyses identify maternal effects as a cause of phenotypic variability in type 1 diabetes and rheumatoid arthritis. Sci Rep  2020; 10(1): 11562.
 [http://dx.doi.org/10.1038/s41598-020-68212-x] [PMID: 32665606]

[24]
Kowluru RA, Mohammad G. Epigenetic modifications in diabetes. Metabolism  2022; 126: 154920.
 [http://dx.doi.org/10.1016/j.metabol.2021.154920] [PMID: 34715117]

[25]
Sinclair DA, LaPlante MD. Lifespan: why we age—and why we don’t have to.  In: Atria books.  2019.

[26]
Wolff EM, Chihara Y, Pan F, et al. Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res  2010; 70(20): 8169-78.
 [http://dx.doi.org/10.1158/0008-5472.CAN-10-1335] [PMID: 20841482]

[27]
Shailesh H, Zakaria ZZ, Baiocchi R, Sif S. Protein arginine methyltransferase 5 (PRMT5) dysregulation in cancer. Oncotarget  2018; 9(94): 36705-18.
 [http://dx.doi.org/10.18632/oncotarget.26404] [PMID: 30613353]

[28]
Hanly DJ, Esteller M, Berdasco M. Interplay between long non-coding RNAs and epigenetic machinery: Emerging targets in cancer? Philos Trans R Soc Lond B Biol Sci  1748; 373(1748): 20170074.
 [http://dx.doi.org/10.1098/rstb.2017.0074]

[29]
Rasmi Y, Shokati A, Hassan A, et al. The role of DNA methylation in progression of neurological disorders and neurodegenerative diseases as well as the prospect of using DNA methylation inhibitors as therapeutic agents for such disorders. IBRO Neuroscience Reports  2023; 14: 28-37.
 [http://dx.doi.org/10.1016/j.ibneur.2022.12.002] [PMID: 36590248]

[30]
Satterlee JS, Chadwick LH, Tyson FL, et al. The NIH common fund/roadmap epigenomics program: Successes of a comprehensive consortium. Sci Adv  2019; 5(7): eaaw6507.
 [http://dx.doi.org/10.1126/sciadv.aaw6507] [PMID: 31501771]

[31]
Phuong J, Riches NO, Madlock-Brown C, et al. Social determinants of health factors for gene–environment COVID‐19 research: challenges and opportunities. Adv Genet  2022; 3(2): 2100056.
 [http://dx.doi.org/10.1002/ggn2.202100056] [PMID: 35574521]

[32]
Duncan LE, Pollastri AR, Smoller JW. Mind the gap: Why many geneticists and psychological scientists have discrepant views about gene–environment interaction (G×E) research. Am Psychol  2014; 69(3): 249-68.
 [http://dx.doi.org/10.1037/a0036320] [PMID: 24750075]

[33]
Bansal A, Pinney SE. DNA methylation and its role in the pathogenesis of diabetes. Pediatr Diabetes  2017; 18(3): 167-77.
 [http://dx.doi.org/10.1111/pedi.12521] [PMID: 28401680]

[34]
Illingworth R, Kerr A, DeSousa D, et al. A novel CpG island set identifies tissue-specific methylation at developmental gene loci. PLoS Biol  2008; 6(1): e22.
 [http://dx.doi.org/10.1371/journal.pbio.0060022] [PMID: 18232738]

[35]
Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis  2010; 31(1): 27-36.
 [http://dx.doi.org/10.1093/carcin/bgp220] [PMID: 19752007]

[36]
Joosten SC, Smits KM, Aarts MJ, et al. Epigenetics in renal cell cancer: Mechanisms and clinical applications. Nat Rev Urol  2018; 15(7): 430-51.
 [http://dx.doi.org/10.1038/s41585-018-0023-z] [PMID: 29867106]

[37]
Lequieu J, Schwartz DC, de Pablo JJ. In silico evidence for sequence-dependent nucleosome sliding. Proc Natl Acad Sci  2017; 114(44): E9197-205.
 [http://dx.doi.org/10.1073/pnas.1705685114] [PMID: 29078285]

[38]
Barnes CE, English DM, Cowley SM. Acetylation & Co: an expanding repertoire of histone acylations regulates chromatin and transcription. Essays Biochem  2019; 63(1): 97-107.
 [http://dx.doi.org/10.1042/EBC20180061] [PMID: 30940741]

[39]
Ouellet V, Negrao J, Skibiel AL, et al. Endocrine signals altered by heat stress impact dairy cow mammary cellular processes at different stages of the dry period. Animals (Basel)  2021; 11(2): 563.
 [http://dx.doi.org/10.3390/ani11020563] [PMID: 33669991]

[40]
Videtic Paska A, Hudler P. Aberrant methylation patterns in cancer: A clinical view. Biochem Med  2015; 25(2): 161-76.
 [http://dx.doi.org/10.11613/BM.2015.017] [PMID: 26110029]

[41]
Song Y, Wang R, Li LW, et al. Long non-coding RNA HOTAIR mediates the switching of histone H3 lysine 27 acetylation to methylation to promote epithelial-to-mesenchymal transition in gastric cancer. Int J Oncol  2018; 54(1): 77-86.
 [http://dx.doi.org/10.3892/ijo.2018.4625] [PMID: 30431069]

[42]
Ma F, Zhang C. Histone modifying enzymes: Novel disease biomarkers and assay development. Expert Rev Mol Diagn  2016; 16(3): 297-306.
 [http://dx.doi.org/10.1586/14737159.2016.1135057] [PMID: 26750583]

[43]
Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science  2017; 357(6348): eaal2380.
 [http://dx.doi.org/10.1126/science.aal2380] [PMID: 28729483]

[44]
Fernandes J, Acuña S, Aoki J, Floeter-Winter L, Muxel S. Long non-coding RNAs in the regulation of gene expression: physiology and disease. Noncoding RNA  2019; 5(1): 17.
 [http://dx.doi.org/10.3390/ncrna5010017] [PMID: 30781588]

[45]
Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: Mechanism of deregulation and clinical implications. Front Oncol  2021; 11: 708765.
 [http://dx.doi.org/10.3389/fonc.2021.708765] [PMID: 34722255]

[46]
Zhou K, Liu M, Cao Y. New insight into microRNA functions in cancer: Oncogene–microRNA–tumor suppressor gene network. Front Mol Biosci  2017; 4: 46.
 [http://dx.doi.org/10.3389/fmolb.2017.00046] [PMID: 28736730]

[47]
Tan T, Shi P, Abbas M, et al. Epigenetic modification regulates tumor progression and metastasis through EMT (Review). Int J Oncol  2022; 60(6): 70.
 [http://dx.doi.org/10.3892/ijo.2022.5360] [PMID: 35445731]

[48]
Kim M, Costello J. DNA methylation: An epigenetic mark of cellular memory. Exp Mol Med  2017; 49(4): 322.
 [http://dx.doi.org/10.1038/emm.2017.10]

[49]
Sánchez OF, Mendonca A, Min A, Liu J, Yuan C. Monitoring histone methylation (H3K9me3) changes in live cells. ACS Omega  2019; 4(8): 13250-9.
 [http://dx.doi.org/10.1021/acsomega.9b01413] [PMID: 31460452]

[50]
Peñaloza E, Soto-Carrasco G, Krause BJ. MiR-21-5p directly contributes to regulating eNOS expression in human artery endothelial cells under normoxia and hypoxia. Biochem Pharmacol  2020; 182: 114288.
 [http://dx.doi.org/10.1016/j.bcp.2020.114288] [PMID: 33075314]

[51]
Smith AR, Smith RG, Pishva E, et al. Parallel profiling of DNA methylation and hydroxymethylation highlights neuropathology-associated epigenetic variation in Alzheimer’s disease. Clin Epigenetics  2019; 11(1): 52.
 [http://dx.doi.org/10.1186/s13148-019-0636-y] [PMID: 30898171]

[52]
Efimova OA, Koltsova AS, Krapivin MI, Tikhonov AV, Pendina AA. Environmental epigenetics and genome flexibility: Focus on 5-hydroxymethylcytosine. Int J Mol Sci  2020; 21(9): 3223.
 [http://dx.doi.org/10.3390/ijms21093223] [PMID: 32370155]

[53]
Ma Q, Yang L, Tolentino K, et al. Inducible lncRNA transgenic mice reveal continual role of HOTAIR in promoting breast cancer metastasis. eLife  2022; 11: e79126.
 [http://dx.doi.org/10.7554/eLife.79126] [PMID: 36579891]

[54]
Yang Y, Luan Y, Feng Q, et al. Epigenetics and beyond: Targeting histone methylation to treat type 2 diabetes mellitus. Front Pharmacol  2022; 12: 807413.
 [http://dx.doi.org/10.3389/fphar.2021.807413] [PMID: 35087408]

[55]
Shtumpf M, Piroeva KV, Agrawal SP, Jacob DR, Teif VB. NucPosDB: A database of nucleosome positioning in vivo and nucleosomics of cell-free DNA. Chromosoma  2022; 131(1-2): 19-28.
 [http://dx.doi.org/10.1007/s00412-021-00766-9] [PMID: 35061087]

[56]
Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: Biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol  2020; 17(2): 111-30.
 [http://dx.doi.org/10.1038/s41575-019-0230-y] [PMID: 31900466]

[57]
Gros C, Fahy J, Halby L, et al. DNA methylation inhibitors in cancer: Recent and future approaches. Biochimie  2012; 94(11): 2280-96.
 [http://dx.doi.org/10.1016/j.biochi.2012.07.025] [PMID: 22967704]

[58]
Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi. Front Oncol  2018; 8: 92.
 [http://dx.doi.org/10.3389/fonc.2018.00092] [PMID: 29651407]

[59]
Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: A novel epigenetic approach. Ann Oncol  2017; 28(8): 1776-87.
 [http://dx.doi.org/10.1093/annonc/mdx157] [PMID: 28838216]

[60]
Rugo HS, Jacobs I, Sharma S, et al. The promise for histone methyltransferase inhibitors for epigenetic therapy in clinical oncology: a narrative review. Adv Ther  2020; 37(7): 3059-82.
 [http://dx.doi.org/10.1007/s12325-020-01379-x] [PMID: 32445185]

[61]
Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer  2008; 123(1): 8-13.
 [http://dx.doi.org/10.1002/ijc.23607] [PMID: 18425818]

[62]
Chebly A, Prochazkova-Carlotti M, Idrissi Y, et al. Targeting epigenetic modifiers can reduce the clonogenic capacities of Sézary cells. Front Oncol  2021; 11: 775253.
 [http://dx.doi.org/10.3389/fonc.2021.775253] [PMID: 34765562]

[63]
Zhao B, Cheng X, Zhou X. The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma. Melanoma Res  2018; 28(6): 521-6.
 [http://dx.doi.org/10.1097/CMR.0000000000000497] [PMID: 30192303]

[64]
Straining R, Eighmy W. Tazemetostat: EZH2 Inhibitor. J Adv Pract Oncol  2022; 13(2): 158-63.
 [http://dx.doi.org/10.6004/jadpro.2022.13.2.7] [PMID: 35369397]

[65]
Evans JS, Beaumont J, Braga M, et al. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy. Eur J Cancer  2022; 176: 110-20.
 [http://dx.doi.org/10.1016/j.ejca.2022.09.009] [PMID: 36208569]

[66]
Greenfield G, McPherson S, Smith J, et al. Modification of the histone landscape with JAK inhibition in myeloproliferative neoplasms. Cancers  2020; 12(9): 2669.
 [http://dx.doi.org/10.3390/cancers12092669] [PMID: 32962027]

[67]
Singh AN, Sharma N. Epigenetic modulators as potential multi-targeted drugs against hedgehog pathway for treatment of cancer. Protein J  2019; 38(5): 537-50.
 [http://dx.doi.org/10.1007/s10930-019-09832-9] [PMID: 30993446]

[68]
Fontecha-Barriuso M, Martin-Sanchez D, Ruiz-Andres O, et al. Targeting epigenetic DNA and histone modifications to treat kidney disease. Nephrol Dial Transplant  2018; 33(11): 1875-86.
 [http://dx.doi.org/10.1093/ndt/gfy009] [PMID: 29534238]

[69]
Kumar VE, Nambiar R, De Souza C, Nguyen A, Chien J, Lam KS. Targeting epigenetic modifiers of tumor plasticity and cancer stem cell behavior. Cells  2022; 11(9): 1403.
 [http://dx.doi.org/10.3390/cells11091403] [PMID: 35563709]

[70]
Falchi L, Ma H, Klein S, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: A multicenter phase 2 study. Blood  2021; 137(16): 2161-70.
 [http://dx.doi.org/10.1182/blood.2020009004] [PMID: 33171487]

[71]
Morabito F, Voso MT, Hohaus S, et al. Panobinostat for the treatment of acute myelogenous leukemia. Expert Opin Investig Drugs  2016; 25(9): 1117-31.
 [http://dx.doi.org/10.1080/13543784.2016.1216971] [PMID: 27485472]

[72]
Wang L, Luo J, Chen G, Fang M, Wei X, Li Y, et al. Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: A single-arm, phase 1/2 study. Clin Epigenet 2020.
 [http://dx.doi.org/10.1186/s13148-020-00923-4]

[73]
Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci  2010; 31(11): 536-46.
 [http://dx.doi.org/10.1016/j.tips.2010.08.001] [PMID: 20846732]

[74]
Saluveer O, Larsson P, Ridderstråle W, Hrafnkelsdóttir TJ, Jern S, Bergh N. Profibrinolytic effect of the epigenetic modifier valproic acid in man. PLoS One  2014; 9(10): e107582.
 [http://dx.doi.org/10.1371/journal.pone.0107582] [PMID: 25295869]

[75]
Zheng YC, Feng SQ. Epigenetic modifications as therapeutic targets. Curr Drug Targets  2020; 21(11): 1046.
 [http://dx.doi.org/10.2174/138945012111200727122724]

[76]
Müller MR, Burmeister A, Skowron MA, et al. Therapeutical interference with the epigenetic landscape of germ cell tumors: a comparative drug study and new mechanistical insights. Clin Epigenetics  2022; 14(1): 5.
 [http://dx.doi.org/10.1186/s13148-021-01223-1] [PMID: 34996497]

[77]
Waters NJ. Preclinical pharmacokinetics and pharmacodynamics of pinometostat (EPZ-5676), a first-in-class, small molecule S-adenosyl methionine competitive inhibitor of DOT1L. Eur J Drug Metab Pharmacokinet  2017; 42(6): 891-901.
 [http://dx.doi.org/10.1007/s13318-017-0404-3] [PMID: 28229434]

[78]
Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr Opin Oncol  2017; 29(5): 375-81.
 [http://dx.doi.org/10.1097/CCO.0000000000000390] [PMID: 28665819]

[79]
Pearson ADJ, DuBois SG, Buenger V, et al. Bromodomain and extra-terminal inhibitors—A consensus prioritisation after the paediatric strategy forum for medicinal product development of epigenetic modifiers in children—ACCELERATE. Eur J Cancer  2021; 146: 115-24.
 [http://dx.doi.org/10.1016/j.ejca.2021.01.018] [PMID: 33601323]

[80]
Borutinskaitė V, Virkšaitė A, Gudelytė G, Navakauskienė R. Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells. Leuk Lymphoma  2018; 59(2): 469-78.
 [http://dx.doi.org/10.1080/10428194.2017.1339881] [PMID: 28641467]

[81]
Rahman Z, Bazaz MR, Devabattula G, Khan MA, Godugu C. Targeting H3K9 methyltransferase G9a and its related molecule GLP as a potential therapeutic strategy for cancer. J Biochem Mol Toxicol  2021; 35(3): e22674.
 [http://dx.doi.org/10.1002/jbt.22674] [PMID: 33283949]

[82]
Lin HY, Wu HJ, Chen SY, Hou MF, Lin CS, Chu PY. Epigenetic therapy combination of UNC0638 and CI-994 suppresses breast cancer via epigenetic remodeling of BIRC5 and GADD45A. Biomed Pharmacother  2022; 145: 112431.
 [http://dx.doi.org/10.1016/j.biopha.2021.112431] [PMID: 34798471]

[83]
Gulati N, Béguelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma  2018; 59(7): 1574-85.
 [http://dx.doi.org/10.1080/10428194.2018.1430795] [PMID: 29473431]

[84]
Pfister SX, Ashworth A. Marked for death: Targeting epigenetic changes in cancer. Nat Rev Drug Discov  2017; 16(4): 241-63.
 [http://dx.doi.org/10.1038/nrd.2016.256] [PMID: 28280262]

[85]
Momparler RL, Momparler LF, Samson J. Comparison of the antileukemic activity of 5-aza-2′-deoxycytidine, 1-β-d-arabinofuranosylcytosine and 5-azacytidine against L1210 leukemia. Leuk Res  1984; 8(6): 1043-9.
 [http://dx.doi.org/10.1016/0145-2126(84)90059-6] [PMID: 6083417]

[86]
Wawruszak A, Borkiewicz L, Okon E, Kukula-Koch W, Afshan S, Halasa M. Vorinostat (SAHA) and breast cancer: An overview. Cancers  2021; 13(18): 4700.
 [http://dx.doi.org/10.3390/cancers13184700] [PMID: 34572928]

[87]
Søgaard OS, Graversen ME, Leth S, et al. The depsipeptide Romidepsin reverses HIV-1 latency in vivo. PLoS Pathog  2015; 11(9): e1005142.
 [http://dx.doi.org/10.1371/journal.ppat.1005142] [PMID: 26379282]

[88]
Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat Med  2016; 22(2): 128-34.
 [http://dx.doi.org/10.1038/nm.4036] [PMID: 26845405]

[89]
Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol  2020; 17(2): 75-90.
 [http://dx.doi.org/10.1038/s41571-019-0266-5] [PMID: 31548600]

[90]
Bruyer A, Maes K, Herviou L, et al. DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. Br J Cancer  2018; 118(8): 1062-73.
 [http://dx.doi.org/10.1038/s41416-018-0025-x] [PMID: 29500406]

[91]
Maio M, Covre A, Fratta E, et al. Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy. Clin Cancer Res  2015; 21(18): 4040-7.
 [http://dx.doi.org/10.1158/1078-0432.CCR-14-2914] [PMID: 26374074]

[92]
Fathi AT, Abdel-Wahab O. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy. Adv Hematol  2012; 2012: 1-12.
 [http://dx.doi.org/10.1155/2012/469592] [PMID: 21811504]

[93]
Mohammad HP, Barbash O, Creasy CL. Targeting epigenetic modifications in cancer therapy: Erasing the roadmap to cancer. Nat Med  2019; 25(3): 403-18.
 [http://dx.doi.org/10.1038/s41591-019-0376-8] [PMID: 30842676]

[94]
Poon CH, Tse LSR, Lim LW. DNA methylation in the pathology of Alzheimer’s disease: From gene to cognition. Ann N Y Acad Sci  2020; 1475(1): 15-33.
 [http://dx.doi.org/10.1111/nyas.14373] [PMID: 32491215]

[95]
Guedes-Dias P, de Proença J, Soares TR, et al. HDAC6 inhibition induces mitochondrial fusion, autophagic flux and reduces diffuse mutant huntingtin in striatal neurons. Biochim Biophys Acta Mol Basis Dis  2015; 1852(11): 2484-93.
 [http://dx.doi.org/10.1016/j.bbadis.2015.08.012] [PMID: 26300485]

[96]
Li E, Zhang Y. DNA methylation in mammals. Cold Spring Harb Perspect Biol  2014; 6(5): a019133.
 [http://dx.doi.org/10.1101/cshperspect.a019133] [PMID: 24789823]

[97]
Barik RR, Bhatt LK. Emerging epigenetic targets in rheumatoid arthritis. Rheumatol Int  2021; 41(12): 2047-67.
 [http://dx.doi.org/10.1007/s00296-021-04951-y] [PMID: 34309725]

[98]
Zhang Y, Zhao M, Sawalha AH, Richardson B, Lu Q. Impaired DNA methylation and its mechanisms in CD4+T cells of systemic lupus erythematosus. J Autoimmun  2013; 41: 92-9.
 [http://dx.doi.org/10.1016/j.jaut.2013.01.005] [PMID: 23340289]

[99]
Kular L, Jagodic M. Epigenetic insights into multiple sclerosis disease progression. J Intern Med  2020; 288(1): 82-102.
 [http://dx.doi.org/10.1111/joim.13045] [PMID: 32614160]

[100]
Natarajan R. Epigenetic mechanisms in diabetic vascular complications and metabolic memory: The 2020 Edwin Bierman Award Lecture. Diabetes  2021; 70(2): 328-37.
 [http://dx.doi.org/10.2337/dbi20-0030] [PMID: 33472942]

[101]
Tran DH, Wang ZV. Glucose metabolism in cardiac hypertrophy and heart failure. J Am Heart Assoc  2019; 8(12): e012673.
 [http://dx.doi.org/10.1161/JAHA.119.012673] [PMID: 31185774]

[102]
Placek K, Schultze JL, Aschenbrenner AC. Epigenetic reprogramming of immune cells in injury, repair, and resolution. J Clin Invest  2019; 129(8): 2994-3005.
 [http://dx.doi.org/10.1172/JCI124619] [PMID: 31329166]

[103]
Ayissi VBO, Ebrahimi A, Schluesenner H. Epigenetic effects of natural polyphenols: A focus on SIRT1‐mediated mechanisms. Mol Nutr Food Res  2014; 58(1): 22-32.
 [http://dx.doi.org/10.1002/mnfr.201300195] [PMID: 23881751]

[104]
Cacabelos R, Torrellas C. Epigenetics of aging and Alzheimer’s disease: Implications for pharmacogenomics and drug response. Int J Mol Sci  2015; 16(12): 30483-543.
 [http://dx.doi.org/10.3390/ijms161226236] [PMID: 26703582]

[105]
Rroji O, Kumar A, Karuppagounder SS, Ratan RR. Epigenetic regulators of neuronal ferroptosis identify novel therapeutics for neurological diseases: HDACs, transglutaminases, and HIF prolyl hydroxylases. Neurobiol Dis  2021; 147: 105145.
 [http://dx.doi.org/10.1016/j.nbd.2020.105145] [PMID: 33127469]

[106]
Ehrhart F, Sangani NB, Curfs LMG. Current developments in the genetics of Rett and Rett-like syndrome. Curr Opin Psychiatry  2018; 31(2): 103-8.
 [http://dx.doi.org/10.1097/YCO.0000000000000389] [PMID: 29206688]

[107]
McCarthy SE, Gillis J, Kramer M, et al. De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability. Mol Psychiatry  2014; 19(6): 652-8.
 [http://dx.doi.org/10.1038/mp.2014.29] [PMID: 24776741]

[108]
Ciechomska M, Roszkowski L, Maslinski W. DNA methylation as a future therapeutic and diagnostic target in rheumatoid arthritis. Cells  2019; 8(9): 953.
 [http://dx.doi.org/10.3390/cells8090953] [PMID: 31443448]

[109]
Mazzone R, Zwergel C, Artico M, et al. The emerging role of epigenetics in human autoimmune disorders. Clin Epigenetics  2019; 11(1): 34.
 [http://dx.doi.org/10.1186/s13148-019-0632-2] [PMID: 30808407]

[110]
Zhang Z, Zhang R. Epigenetics in autoimmune diseases: Pathogenesis and prospects for therapy. Autoimmun Rev  2015; 14(10): 854-63.
 [http://dx.doi.org/10.1016/j.autrev.2015.05.008] [PMID: 26026695]

[111]
Nicorescu I, Dallinga GM, de Winther MPJ, Stroes ESG, Bahjat M. Potential epigenetic therapeutics for atherosclerosis treatment. Atherosclerosis  2019; 281: 189-97.
 [http://dx.doi.org/10.1016/j.atherosclerosis.2018.10.006] [PMID: 30340764]

[112]
Prasher D, Greenway SC, Singh RB. The impact of epigenetics on cardiovascular disease. Biochem Cell Biol  2020; 98(1): 12-22.
 [http://dx.doi.org/10.1139/bcb-2019-0045] [PMID: 31112654]

[113]
Arif M, Sadayappan S, Becker RC, Martin LJ, Urbina EM. Epigenetic modification: A regulatory mechanism in essential hypertension. Hypertens Res  2019; 42(8): 1099-113.
 [http://dx.doi.org/10.1038/s41440-019-0248-0] [PMID: 30867575]

[114]
Bianco-Miotto T, Craig JM, Gasser YP, van Dijk SJ, Ozanne SE. Epigenetics and DOHaD: From basics to birth and beyond. J Dev Orig Health Dis  2017; 8(5): 513-9.
 [http://dx.doi.org/10.1017/S2040174417000733] [PMID: 28889823]

[115]
Stols-Gonçalves D, Tristão LS, Henneman P, Nieuwdorp M. Epigenetic markers and microbiota/metabolite-induced epigenetic modifications in the pathogenesis of obesity, metabolic syndrome, type 2 diabetes, and non-alcoholic fatty liver disease. Curr Diab Rep  2019; 19(6): 31.
 [http://dx.doi.org/10.1007/s11892-019-1151-4] [PMID: 31044315]

[116]
Hoang TT, Sikdar S, Xu CJ, et al. Epigenome-wide association study of DNA methylation and adult asthma in the Agricultural Lung Health Study. Eur Respir J  2020; 56(3): 2000217.
 [http://dx.doi.org/10.1183/13993003.00217-2020] [PMID: 32381493]

[117]
Shanmugam G, Sunny JS, Rakshit S, George M, Leela KV, Sarkar K. Involvement of inflammatory cytokines and epigenetic modification of the mtTFA complex in T-helper cells of patients’ suffering from non-small cell lung cancer and chronic obstructive pulmonary disease. Mol Immunol  2022; 151: 70-83.
 [http://dx.doi.org/10.1016/j.molimm.2022.08.006] [PMID: 36099831]

[118]
Grote C, Reinhardt D, Zhang M, Wang J. Regulatory mechanisms and clinical manifestations of musculoskeletal aging. J Orthop Res  2019; 37(7): 1475-88.
 [http://dx.doi.org/10.1002/jor.24292] [PMID: 30919498]

[119]
Moufarrij S, Dandapani M, Arthofer E, et al. Epigenetic therapy for ovarian cancer: Promise and progress. Clin Epigenetics  2019; 11(1): 7.
 [http://dx.doi.org/10.1186/s13148-018-0602-0] [PMID: 30646939]

[120]
Caradus JR. Intended and unintended consequences of genetically modified crops–myth, fact and/or manageable outcomes. N Z J Agric Res  2022; 01: 1-101.
 [http://dx.doi.org/10.1080/00288233.2022.2141273]

[121]
Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist  2019; 2(2): 141-60.
 [http://dx.doi.org/10.20517/cdr.2019.10] [PMID: 34322663]

[122]
Hamdani N, Costantino S, Mügge A, et al. Leveraging clinical epigenetics in heart failure with preserved ejection fraction: A call for individualized therapies. Eur Heart J  2021; 42(20): 1940-58.
 [http://dx.doi.org/10.1093/eurheartj/ehab197]

[123]
Roberti A, Valdes AF, Torrecillas R, Fraga MF, Fernandez AF. Epigenetics in cancer therapy and nanomedicine. Clin Epigenetics  2019; 11(1): 81.
 [http://dx.doi.org/10.1186/s13148-019-0675-4] [PMID: 31097014]

[124]
Coussens NP, Sittampalam GS, Jonson SG, et al. The opioid crisis and the future of addiction and pain therapeutics. J Pharmacol Exp Ther  2019; 371(2): 396-408.
 [http://dx.doi.org/10.1124/jpet.119.259408] [PMID: 31481516]

[125]
Brown WA. Expectation, the placebo effect and the response to treatment. R I Med J  2013; 98(5): 19-21.

[126]
Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater  2021; 6(4): 351-70.
 [http://dx.doi.org/10.1038/s41578-020-00269-6] [PMID: 34950512]

[127]
Wathoni N, Puluhulawa LE, Joni IM, et al. Monoclonal antibody as a targeting mediator for nanoparticle targeted delivery system for lung cancer. Drug Deliv  2022; 29(1): 2959-70.
 [http://dx.doi.org/10.1080/10717544.2022.2120566] [PMID: 36085575]

[128]
Marshall HT, Djamgoz MBA. Immuno-oncology: Emerging targets and combination therapies. Front Oncol  2018; 8: 315.
 [http://dx.doi.org/10.3389/fonc.2018.00315] [PMID: 30191140]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0115748855275769231114094037	Print ISSN 1574-8855
Publisher Name Bentham Science Publisher	Online ISSN 2212-3903

Current Drug Therapy

Targeting Epigenetic Modifiers: Promising Strategies for Cancer Therapy and Beyond

Abstract Play Pause

Related Journals

Related Books

Abstract